Background

farmaec

FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology

ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология

2070-49092070-4933

IRBIS LLC

10.17749/2070-4909/farmakoekonomika.2024.285

farmaec-1103

Research Article

ORIGINAL ARTICLES

ОРИГИНАЛЬНЫЕ ПУБЛИКАЦИИ

Proteomic analysis of synergetic neuroprotective effect of adenosine, thiamine, niacin and cyanocobalamin in pathophysiology of diabetic polyneuropathy

Протеомный анализ синергетического нейропротекторного действия аденозина, тиамина, ниацина и цианокобаламина в патофизиологии диабетической полинейропатии

https://orcid.org/0000-0002-7663-710X

Громова

О. А.

Gromova

O. A.

Громова Ольга Алексеевна - д.м.н., проф. WoS ResearcherID: J-4946-2017. Scopus Author ID: 7003589812. eLibrary SPIN-code: 6317-9833.

Ул. Вавилова, д. 44, корп. 2, Москва 119333

Olga A. Gromova - Dr. Sci. Med., Prof. WoS ResearcherID: J-4946-2017. Scopus Author ID: 7003589812. eLibrary SPIN-code: 6317-9833.

44 corp. 2 Vavilov Str., Moscow 119333, Russia

unesco.gromova@gmail.com

https://orcid.org/0000-0002-2659-7998

Торшин

И. Ю.

Torshin

I. Yu.

Торшин Иван Юрьевич - к.ф-м.н., к.х.н. WoS ResearcherID: C-7683-2018. Scopus Author ID: 7003300274. eLibrary SPIN-code: 1375-1114.

Ул. Вавилова, д. 44, корп. 2, Москва 119333

Ivan Yu. Torshin - PhD (Phys. Math.), PhD (Chem.) . WoS ResearcherID: C-7683-2018. Scopus Author ID: 7003300274. eLibrary SPIN-code: 1375-1114.

44 corp. 2 Vavilov Str., Moscow 119333, Russia

https://orcid.org/0000-0002-9422-5248

Мойсеенок

А. Г.

Moiseenok

A. G.

Мойсеенок Андрей Георгиевич - д.м.н., проф., академик БАН.

Пл. Антония Тызенгауза, д. 7, Гродно 230023

Andrey G. Moiseenok - Dr. Sci. Med., Prof., Member of BAS.

7 Antoniy Tyzengauz Sq., Grodno 230023, Belarus

Федеральный исследовательский центр «Информатика и управление» Российской академии наукРоссияFederal Research Center “Computer Science and Control”, Russian Academy of SciencesRussian Federation

Республиканское научно-исследовательское унитарное предприятие «Институт биохимии биологически активных соединений Национальной академии наук Беларуси»БеларусьInstitute of Biochemistry of Biologically Active Compounds, National Academy of Sciences of BelarusBelarus

2024

20022025

174542557

2025

Громова О.А., Торшин И.Ю., Мойсеенок А.Г.

Gromova O.A., Torshin I.Y., Moiseenok A.G.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.pharmacoeconomics.ru/jour/article/view/1103

Background

Background. Neurotransmitter adenosine and B-group vitamins have neuroprotective, remyelinizing and anti-neuroinflammatory properties. Despite the studies of these molecules for decades, the molecular mechanisms of their synergistic effect on neuroinflammation processes are unexplored and not systematized.

Objective

Objective: to establish the molecular mechanisms of synergism of adenosine, thiamine, niacin and cyanocobalamin in counteracting the pathology of diabetic polyneuropathy (DPN).

Material and methods

Material and methods. The molecular mechanisms of action of adenosine, thiamine (vitamin B1), niacin (vitamin PP) and cyanocobalamin (vitamin B12) in the pathophysiology of DPN were determined using functional analysis of genomic and proteomic databases.

Results

Results. The analysis of 20,180 annotated proteins of the human proteome identified 504 vitamin-PP-dependent, 22 vitamin-B1-dependent, 24 vitamin-B12-dependent and 50 adenosine-dependent proteins. The proteins of the human proteome were detected, the activity or levels of which are important for reducing neuroinflammation, remyelination, neurogenesis, biosynthesis of neuronal adenosine triphosphate, myelin homeostasis, neuroplasticity, neutralization of homocysteine, regeneration of nerve fibers and maintaining the endothelium of the microvascular bed.

Conclusion

Conclusion. The discovered molecular mechanisms of synergism of the studied molecules are of fundamental importance for comprehension of the processes of neuroinflammation regulation and remyelination to prevent diabetic polyneuropathy and other neurodegenerative diseases.

Актуальность

Актуальность. Нейротрансмиттер аденозин и витамины группы В характеризуются нейропротекторными, ремиелинизирующими и противонейровоспалительными свойствами. Несмотря на исследования этих молекул в течение десятилетий, молекулярные механизмы синергизма их влияния на процессы нейровоспаления не изучены и не систематизированы.

Цель

Цель: установление молекулярных механизмов синергизма аденозина, тиамина, ниацина и цианокобаламина в противодействии патологии диабетической полинейропатии (ДПН).

Материал и методы

Материал и методы. Определение молекулярных механизмов действия аденозина, тиамина (витамин В1), ниацина (витамин РР) и цианокобаламина (витамин В12) в патофизиологии ДПН проведено посредством функционального анализа геномных и протеомных баз данных.

Результаты

Результаты. В результате проведенного анализа из 20 180 аннотированных белков протеома человека выделено 504 витамин-РРзависимых, 22 витамин-В1-зависимых, 24 витамин-В12-зависимых и 50 аденозин-зависимых. Установлены белки протеома человека, активность или уровни которых важны для снижения нейровоспаления, ремиелинизации, нейрогенеза, биосинтеза нейронального аденозинтрифосфата, гомеостаза миелина, нейропластичности, обезвреживания гомоцистеина, регенерации нервных волокон и поддержки эндотелия микрососудистого русла.

Заключение

Заключение. Установленные молекулярные механизмы синергизма изученных молекул имеют фундаментальное значение для понимания процессов регуляции нейровоспаления и ремиелинизации в целях профилактики ДПН и других нейродегенеративных заболеваний.

Аденозинвитамины группы Внейровоспалениедиабетическая полинейропатиябиоинформатикафармакоинформатикасинергизмКокарнит

AdenosineB-group vitaminsneuroinflammationdiabetic polyneuropathybioinformaticspharmacoinformaticssynergismCocarnit

References1

Khatun S., Prasad Bhagat R., Dutta R., et al. Unraveling HDAC11: epigenetic orchestra in different diseases and structural insights for inhibitor design. Biochem Pharmacol. 2024; 225: 116312. https://doi.org/10.1016/j.bcp.2024.116312.

Dyck P.J., Albers J.W., Andersen H., et al. Diabetic polyneuropathies: update on research definition, diagnostic criteria and estimation of severity. Diabetes Metab Res Rev. 2011; 27 (7): 620–8. https://doi.org/10.1002/dmrr.1226.

Lipsky B.A., Senneville E., Abbas Z.G., et al. Guidelines on the diagnosis and treatment of foot infection in persons with diabetes (IWGDF 2019 update). Diabetes Metab Res Rev. 2020; 36 (Suppl. 1): e3280. https://doi.org/10.1002/dmrr.3280.

Goldney J., Barker M.M., Thomas M., et al. Age at onset of type 2 diabetes and prevalence of vascular disease and heart failure: Systematic review and dose-response meta-analysis. J Diabetes Complications. 2024; 38 (10): 108849. https://doi.org/10.1016/j.jdiacomp.2024.108849.

Галстян Г.Р., Старостина Е.Г., Яхно Н.Н. и др. Диагностика и рациональная терапия болевой формы диабетической периферической нейропатии: междисциплинарный консенсус экспертов. Сахарный диабет. 2019; 22 (4): 305–27. https://doi.org/10.14341/DM9625.

Galstyan G.R., Starostina E.G., Yakhno N.N., et al. Diagnosis and rational treatment of painful diabetic peripheral neuropathy: an interdisciplinary expert consensus. Diabetes Mellitus. 2019; 22 (4): 305–27 (in Russ.). https://doi.org/10.14341/DM9625.

Senneville E., Albalawi Z., van Asten S.A., et al. IWGDF/IDSA guidelines on the diagnosis and treatment of diabetes-related foot infections (IWGDF/IDSA 2023). Diabetes Metab Res Rev. 2024; 40 (3): e3687. https://doi.org/10.1002/dmrr.3687.

Roikjer J., Wegeberg A.M., Nikontovic A., et al. Prevalence of painful and painless diabetic peripheral neuropathy in the Northern Danish Region: a population-based study. Prim Care Diabetes. 2024: S1751-9918(24)00164-5. https://doi.org/10.1016/j.pcd.2024.08.006.

Shrimpton M., Shaw C. Concurrent transverse myelitis and acute inflammatory demyelinating polyneuropathy. BMJ Case Rep. 2024; 17 (5): e259732. https://doi.org/10.1136/bcr-2024-259732.

Vincent A.M., Callaghan B.C., Smith A.L., Feldman E.L. Diabetic neuropathy: cellular mechanisms as therapeutic targets. Nat Rev Neurol. 2011; 7 (10): 573–83. https://doi.org/10.1038/nrneurol.2011.137.

Niimi N., Yako H., Takaku S., et al. Aldose reductase and the polyol pathway in schwann cells: old and new problems. Int J Mol Sci. 2021; 22 (3): 1031. https://doi.org/10.3390/ijms22031031.

Aziz N., Dash B., Wal P., et al. New horizons in diabetic neuropathies: an updated review on their pathology, diagnosis, mechanism, screening techniques, pharmacological, and future approaches. Curr Diabetes Rev. 2024; 20 (6): e201023222416. https://doi.org/10.2174/0115733998242299231011181615.

Liang Z., Zhang N., Wang X., et al. Corrigendum to “Epothilone B inactivation of Sirtuin1 promotes mitochondrial reactive oxygen species to induce dysfunction and ferroptosis of Schwann cells” [European Journal of Pharmaeutical Sciences 181 (2023) 106350]. Eur J Pharm Sci. 2024:106854. https://doi.org/10.1016/j.ejps.2024.106854.

Chong Z.Z., Menkes D.L., Souayah N. Targeting neuroinflammation in distal symmetrical polyneuropathy in diabetes. Drug Discov Today. 2024; 29 (8): 104087. https://doi.org/10.1016/j.drudis.2024.104087.

Громова О.А., Торшин И.Ю., Путилина М.В. и др. О механизмах синергидного действия толперизона, мелоксикама и витаминов группы В в терапии периферических болевых синдромов. Медицинский совет. 2020; 8: 54–64. https://doi.org/10.21518/2079-701X-2020-8-54-64.

Gromova O.A., Torshin I.Y., Putilina M.V., et al. On the mechanisms of the synergistic action of tolperisone, meloxicam and B vitamins in the treatment of peripheral pain syndromes. Meditsinskiy sovet / Medical Council. 2020; 8: 54–64 (in Russ.). https://doi.org/10.21518/2079-701X-2020-8-54-64.

Громова О.А., Торшин И.Ю., Тапильская Н.И., Галустян А.Н. Системно-биологический анализ синергидного воздействия прогестерона, витаминов и микроэлементов на нейропротекцию и развитие мозга плода. Вопросы гинекологии, акушерства и перинатологии.2019; 18 (6): 65–75. https://doi.org/10.20953/1726-1678-2019-6-65-75.

Gromova O.A., Torshin I.Yu., Tapilskaya N.I., Galustyan A.N. Systemicbiological analysis of synergic impact of progesterone, vitamins and trace elements on neuroprotection and fetal brain development. Gynecology, Obstetrics and Perinatology. 2019; 18 (6): 65–75 (in Russ.). https://doi.org/10.20953/1726-1678-2019-6-65-75.

Torshin I.Yu. Sensing the change: from molecular genetics to personalized medicine. Nova Science Pub Inc.; 2012: 366 pp.

Huang Z.L., Urade Y., Hayaishi O. The role of adenosine in the regulation of sleep. Curr Top Med Chem. 2011; 11 (8): 1047–57. https://doi.org/10.2174/156802611795347654.

Schettler G. The role of the physician in political environmental discussions. Offentl Gesundheitswes. 1990; 52 (Suppl. 1): 7–11 (in German).

Chen Z., Xiong C., Pancyr C., et al. Prolonged adenosine A1 receptor activation in hypoxia and pial vessel disruption focal cortical ischemia facilitates clathrin-mediated AMPA receptor endocytosis and longlasting synaptic inhibition in rat hippocampal CA3-CA1 synapses: differential regula. J Neurosci. 2014; 34 (29): 9621–43. https://doi.org/10.1523/JNEUROSCI.3991-13.2014.

Atkinson M.R., Townsend-Nicholson A., Nicholl J.K., et al. Cloning, characterisation and chromosomal assignment of the human adenosine A3 receptor (ADORA3) gene. Neurosci Res. 1997; 29 (1): 73–9. https://doi.org/10.1016/s0168-0102(97)00073-4.

Wan T.C., Ge Z.D., Tampo A., et al. The A3 adenosine receptor agonist CP-532,903 [N6-(2,5-dichlorobenzyl)-3'-aminoadenosine-5'N-methylcarboxamide] protects against myocardial ischemia/ reperfusion injury via the sarcolemmal ATP-sensitive potassium channel. J Pharmacol Exp Ther. 2008; 324 (1): 234–43. https://doi.org/10.1124/jpet.107.127480.

Smith R.G., Leonard R., Bailey A.R., et al. Growth hormone secretagogue receptor family members and ligands. Endocrine. 2001; 14 (1): 9–14. https://doi.org/10.1385/ENDO:14:1:009.

Huang Z., Chen C., Guan K., et al. Protective role of ghrelin against 6PPD-quinone-induced neurotoxicity in zebrafish larvae (Danio rerio) via the GHSR pathway. Ecotoxicol Environ Saf. 2024; 285: 117031. https://doi.org/10.1016/j.ecoenv.2024.117031.

Salpietro V., Dixon C.L., Guo H., et al. AMPA receptor GluA2 subunit defects are a cause of neurodevelopmental disorders. Nat Commun. 2019; 10 (1): 3094. https://doi.org/10.1038/s41467-019-10910-w.

Kolleker A., Zhu J.J., Schupp B.J., et al. Glutamatergic plasticity by synaptic delivery of GluR-B(long)-containing AMPA receptors. Neuron. 2003; 40 (6): 1199–212. https://doi.org/10.1016/s0896-6273(03)00722-0.

Qin X., Zaki M.G., Chen Z., et al. Adenosine signaling and clathrinmediated endocytosis of glutamate AMPA receptors in delayed hypoxic injury in rat hippocampus: role of casein kinase 2. Mol Neurobiol. 2021; 58 (5): 1932–51. https://doi.org/10.1007/s12035-020-02246-0.

Kozich V., Sokolová J., Klatovská V., et al. Cystathionine betasynthase mutations: effect of mutation topology on folding and activity. Hum Mutat. 2010; 31 (7): 809–19. https://doi.org/10.1002/humu.21273.

Casique L., Kabil O., Banerjee R., et al. Characterization of two pathogenic mutations in cystathionine beta-synthase: different intracellular locations for wild-type and mutant proteins. Gene. 2013; 531 (1): 117–24. https://doi.org/10.1016/j.gene.2013.08.021.

Witucki Ł., Jakubowski H. Homocysteine metabolites inhibit autophagy, elevate amyloid beta, and induce neuropathy by impairing Phf8/H4K20me1-dependent epigenetic regulation of mTOR in cystathionine β-synthase-deficient mice. J Inherit Metab Dis. 2023; 46 (6): 1114–30. https://doi.org/10.1002/jimd.12661.

Wang F., Zhou H., Zhang X. SAM, a cystathionine beta-synthase activator, promotes hydrogen sulfide to promote neural repair resulting from massive cerebral infarction induced by middle cerebral artery occlusion. Metab Brain Dis. 2022; 37 (5): 1641–54. https://doi.org/10.1007/s11011-022-00976-9.

Yin W.L., Yin W.G., Huang B.S., Wu L.X. Neuroprotective effects of lentivirus-mediated cystathionine-beta-synthase overexpression against 6-OHDA-induced Parkinson's disease rats. Neurosci Lett. 2017; 657: 45–52. https://doi.org/10.1016/j.neulet.2017.07.019.

Shields D.J., Lingrell S., Agellon L.B., et al. Localization-independent regulation of homocysteine secretion by phosphatidylethanolamine N-methyltransferase. J Biol Chem. 2005; 280 (29): 27339–44. https:// doi.org/10.1074/jbc.M504658200.

Wittmann G., Liposits Z., Lechan R.M., Fekete C. Medullary adrenergic neurons contribute to the cocaineand amphetamineregulated transcript-immunoreactive innervation of thyrotropinreleasing hormone synthesizing neurons in the hypothalamic paraventricular nucleus. Brain Res. 2004; 1006 (1): 1–7. https://doi.org/10.1016/j.brainres.2003.12.049.

Alarcón C.R., Goodarzi H., Lee H., et al. HNRNPA2B1 is a mediator of m(6)A-dependent nuclear RNA processing events. Cell. 2015; 162 (6): 1299–308. https://doi.org/10.1016/j.cell.2015.08.011.

Ke S., Pandya-Jones A., Saito Y., et al. m(6)A mRNA modifications are deposited in nascent pre-mRNA and are not required for splicing but do specify cytoplasmic turnover. Genes Dev. 2017; 31 (10): 990–1006. https://doi.org/10.1101/gad.301036.117.

Wu L., Ning P., Liang Y., et al. Methyltransferase METTL3 regulates neuropathic pain through m6A methylation modification of SOCS1. Neuropharmacology. 2024; 261: 110176. https://doi.org/10.1016/j.neuropharm.2024.110176.

Dermentzaki G., Furlan M., Tanaka I., et al. Depletion of Mettl3 in cholinergic neurons causes adult-onset neuromuscular degeneration. Cell Rep. 2024; 43 (4): 113999. https://doi.org/10.1016/j.celrep.2024.113999.

Ming Y., Deng Z., Tian X., et al. m6A Methyltransferase METTL3 reduces hippocampal neuron apoptosis in a mouse model of autism through the MALAT1/SFRP2/Wnt/β-catenin axis. Psychiatry Investig. 2022; 19 (10): 771–87. https://doi.org/10.30773/pi.2021.0370.

Liu B., Xing Z., Song F., et al. METTL3-mediated ANXA2 inhibition confers neuroprotection in ischemic stroke: evidence from in vivo and in vitro studies. FASEB J. 2023; 37 (7): e22974. https://doi.org/10.1096/fj.202300246R.

Kato M., Wynn R.M., Chuang J.L., et al. Structural basis for inactivation of the human pyruvate dehydrogenase complex by phosphorylation: role of disordered phosphorylation loops. Structure. 2008; 16 (12): 1849–59. https://doi.org/10.1016/j.str.2008.10.010.

Ferreira T., Polavarapu K., Olimpio C., et al. Variants in mitochondrial disease genes are common causes of inherited peripheral neuropathies. J Neurol. 2024; 271 (6): 3546–53. https://doi.org/10.1007/s00415-024-12319-y.

Mizusawa A., Watanabe A., Yamada M., et al. BDK deficiency in cerebral cortex neurons causes neurological abnormalities and affects endurance capacity. Nutrients. 2020; 12 (8): 2267. https://doi.org/10.3390/nu12082267.

Joshi M.A., Jeoung N.H., Obayashi M., et al. Impaired growth and neurological abnormalities in branched-chain alpha-keto acid dehydrogenase kinase-deficient mice. Biochem J. 2006; 400 (1): 153–62. https://doi.org/10.1042/BJ20060869.

Li T., Zhao L., Li Y., Dang M., et al. PPM1K mediates metabolic disorder of branched-chain amino acid and regulates cerebral ischemiareperfusion injury by activating ferroptosis in neurons. Cell Death Dis. 2023; 14 (9): 634. https://doi.org/10.1038/s41419-023-06135-x.

Gao R., Liu Z., Meng M., et al. Neurogenesis-associated protein, a potential prognostic biomarker in anti-PD-1 based kidney renal clear cell carcinoma patient therapeutics. Pharmaceuticals. 2024; 17 (4): 451. https://doi.org/10.3390/ph17040451.

Pinson A., Xing L., Namba T., et al. Human TKTL1 implies greater neurogenesis in frontal neocor tex of modern humans than Neanderthals. Science. 2022; 377 (6611): eabl6422. https://doi.org/10.1126/science.abl6422.

Coy J.F., Dressler D., Wilde J., Schubert P. Mutations in the transketolase-like gene TKTL1: clinical implications for neurodegenerative diseases, diabetes and cancer. Clin Lab. 2005; 51 (5–6): 257–73.

Liu Y., Meng F., Wang J., et al. A novel oxoglutarate dehydrogenaselike mediated miR-214/TWIST1 negative feedback loop inhibits pancreatic cancer growth and metastasis. Clin Cancer Res. 2019; 25 (17): 5407–21. https://doi.org/10.1158/1078-0432.CCR-18-4113.

Yap Z.Y., Efthymiou S., Seiffert S., et al. Bi-allelic variants in OGDHL cause a neurodevelopmental spectrum disease featuring epilepsy, hearing loss, visual impairment, and ataxia. Am J Hum Genet. 2021; 108 (12): 2368–84. https://doi.org/10.1016/j.ajhg.2021.11.003.

Громова О.А., Торшин И.Ю. Систематический анализ экспериментальной и клинической фармакологии никотинамида и перспективы лечения атеросклероза. Экспериментальная и клиническая гастроэнтерология. 2022; 10: 111–25. https://doi.org/10.31146/1682-8658-ecg-206-10-111-125.

Gromova O.A., Torshin I.Yu. Systematic analysis of the experimental and clinical pharmacology of nicotinamide and prospects for the treatment of atherosclerosis. Experimental and Clinical Gastroenterology. 2022; 10: 111–25 (in Russ.). https://doi.org/10.31146/1682-8658-ecg-206-10-111-125.

Kostylina G., Simon D., Fey M.F., et al. Neutrophil apoptosis mediated by nicotinic acid receptors (GPR109A). Cell Death Differ. 2008; 15 (1): 134–42. https://doi.org/10.1038/sj.cdd.4402238.

Wuerch E., Urgoiti G.R., Yong V.W. The promise of niacin in neurology. Neurotherapeutics. 2023; 20 (4): 1037–54. https://doi.org/10.1007/s13311-023-01376-2.

Challa S., Khulpateea B.R., Nandu T., et al. Ribosome ADPribosylation inhibits translation and maintains proteostasis in cancers. Cell. 2021; 184 (17): 4531–46.e26. https://doi.org/10.1016/j.cell.2021.07.005.

Berger F., Lau C., Dahlmann M., Ziegler M. Subcellular compartmentation and differential catalytic properties of the three human nicotinamide mononucleotide adenylyltransferase isoforms. J Biol Chem. 2005; 280 (43): 36334–41. https://doi.org/10.1074/jbc.M508660200.

Kotaka M., Gover S., Vandeputte-Rutten L., et al. Structural studies of glucose-6-phosphate and NADP+ binding to human glucose-6phosphate dehydrogenase. Acta Crystallogr D Biol Crystallogr. 2005; 61 (Pt. 5): 495–504. https://doi.org/10.1107/S0907444905002350.

Sun Q., Zhang B.Y., Zhang P.A., et al. Downregulation of glucose-6-phosphate dehydrogenase contributes to diabetic neuropathic pain through upregulation of toll-like receptor 4 in rats. Mol Pain. 2019; 15: 1744806919838659. https://doi.org/10.1177/1744806919838659.

Chen X., Gu X., Shan Y., et al. Identification of a novel human lactate dehydrogenase gene LDHAL6A, which activates transcriptional activities of AP1(PMA). Mol Biol Rep. 2009; 36 (4): 669–76. https://doi.org/10.1007/s11033-008-9227-2.

Yuan Z., Zhang X., Sengupta N., et al. SIRT1 regulates the function of the Nijmegen breakage syndrome protein. Mol Cell. 2007; 27 (1): 149–62. https://doi.org/10.1016/j.molcel.2007.05.029.

Uhl M., Csernok A., Aydin S., et al. Role of SIRT1 in homologous recombination. DNA Repair. 2010; 9 (4): 383–93. https://doi.org/10.1016/j.dnarep.2009.12.020.

Vaquero A., Scher M., Lee D., et al. Human SirT1 interacts with histone H1 and promotes formation of facultative heterochromatin. Mol Cell. 2004; 16 (1): 93–105. https://doi.org/10.1016/j.molcel.2004.08.031.

Bosch-Presegué L., Raurell-Vila H., Marazuela-Duque A., et al. Stabilization of Suv39H1 by SirT1 is part of oxidative stress response and ensures genome protection. Mol Cell. 2011; 42 (2): 210–23. https://doi.org/10.1016/j.molcel.2011.02.034.

Yeung F., Hoberg J.E., Ramsey C.S., et al. Modulation of NF-kappaBdependent transcription and cell survival by the SIRT1 deacetylase. EMBO J. 2004; 23 (12): 2369–80. https://doi.org/10.1038/sj.emboj.7600244.

Sundaresan N.R., Pillai V.B., Wolfgeher D., et al. The deacetylase SIRT1 promotes membrane localization and activation of Akt and PDK1 during tumorigenesis and cardiac hypertrophy. Sci Signal. 2011; 4 (182): ra46. https://doi.org/10.1126/scisignal.2001465.

Wang J., Chen J. SIRT1 regulates autoacetylation and histone acetyltransferase activity of TIP60. J Biol Chem. 2010; 285 (15): 11458–64. https://doi.org/10.1074/jbc.M109.087585.

Thapa R., Moglad E., Afzal M., et al. The role of sirtuin 1 in ageing and neurodegenerative disease: a molecular perspective. Ageing Res Rev. 2024; 102: 102545. https://doi.org/10.1016/j.arr.2024.102545.

Zach S., Felk S., Gillardon F. Signal transduction protein array analysis links LRRK2 to Ste20 kinases and PKC zeta that modulate neuronal plasticity. PLoS One. 2010; 5 (10): e13191. https://doi.org/10.1371/journal.pone.0013191.

Piccoli G., Onofri F., Cirnaru M.D., et al. Leucine-rich repeat kinase 2 binds to neuronal vesicles through protein interactions mediated by its C-terminal WD40 domain. Mol Cell Biol. 2014; 34 (12): 2147–61. https://doi.org/10.1128/MCB.00914-13.

Gómez-Suaga P., Luzón-Toro B., Churamani D., et al. Leucine-rich repeat kinase 2 regulates autophagy through a calcium-dependent pathway involving NAADP. Hum Mol Genet. 2012; 21 (3): 511–25. https://doi.org/10.1093/hmg/ddr481.

Громова О.А., Стаховская Л.В., Торшин И.Ю., Томилова И.К. Прием метформина провоцирует нарушения гомеостаза витамина В12. Consilium Medicum. 2017; 19 (4): 58–64.

Gromova O.A., Stakhovskaya L.V., Torshin I.Yu., Tomilova I.K. The application of metformin provokes disturbance in vitamin B12 homeostasis. Consilium Medicum. 2017; 19 (4): 58–64 (in Russ.).

Wolthers K.R., Toogood H.S., Jowitt T.A., et al. Crystal structure and solution characterization of the activation domain of human methionine synthase. FEBS J. 2007; 274 (3): 738–50. https://doi.org/10.1111/j.1742-4658.2006.05618.x.

Hassan Z., Coelho D., Bossenmeyer-Pourié C., et al. Cognitive impairment is associated with AMPAR glutamatergic dysfunction in a mouse model of neuronal methionine synthase deficiency. Cells. 2023; 12 (9): 1267. https://doi.org/10.3390/cells12091267.

Takahashi-Íñiguez T., García-Arellano H., Trujillo-Roldán M.A., Flores M.E. Protection and reactivation of human methylmalonyl-CoA mutase by MMAA protein. Biochem Biophys Res Commun. 2011; 404 (1): 443–7. https://doi.org/10.1016/j.bbrc.2010.11.141.

Wolthers K.R., Lou X., Toogood H.S., et al. Mechanism of coenzyme binding to human methionine synthase reductase revealed through the crystal structure of the FNR-like module and isothermal titration calorimetry. Biochemistry. 2007; 46 (42): 11833–44. https://doi.org/10.1021/bi701209p.

Jadavji N.M., Bahous R.H., Deng L., et al. Mouse model for deficiency of methionine synthase reductase exhibits short-term memory impairment and disturbances in brain choline metabolism. Biochem J. 2014; 461 (2): 205–12. https://doi.org/10.1042/BJ20131568.

Wolthers K.R., Scrutton N.S. Cobalamin uptake and reactivation occurs through specific protein interactions in the methionine synthasemethionine synthase reductase complex. FEBS J. 2009; 276 (7): 1942–51. https://doi.org/10.1111/j.1742-4658.2009.06919.x.

Kim J., Gherasim C., Banerjee R. Decyanation of vitamin B12 by a trafficking chaperone. Proc Natl Acad Sci USA. 2008; 105 (38): 14551–4. https://doi.org/10.1073/pnas.0805989105.

Kim J., Hannibal L., Gherasim C., et al. A human vitamin B12 trafficking protein uses glutathione transferase activity for processing alkylcobalamins. J Biol Chem. 2009; 284 (48): 33418–24. https://doi.org/10.1074/jbc.M109.057877.

Taylor J.M., Allen A.M., Graham A. Targeting mitochondrial 18 kDa translocator protein (TSPO) regulates macrophage cholesterol efflux and lipid phenotype. Clin Sci. 2014; 127 (10): 603–13. https://doi.org/10.1042/CS20140047.

Liu J., Huang J., Zhang Z., Zhang R., et al. Translocator protein 18 kDa (TSPO) as a novel therapeutic target for chronic pain. Neural Plast. 2022; 2022: 8057854. https://doi.org/10.1155/2022/8057854.

Bettendorff L., Goessens G., Sluse F., et al. Thiamine deficiency in cultured neuroblastoma cells: effect on mitochondrial function and peripheral benzodiazepine receptors. J Neurochem. 1995; 64 (5): 2013–21. https://doi.org/10.1046/j.1471-4159.1995.64052013.x.

El Hajj Chehadeh S., Dreumont N., Willekens J., et al. Early methyl donor deficiency alters cAMP signaling pathway and neurosteroidogenesis in the cerebellum of female rat pups. Am J Physiol Endocrinol Metab. 2014; 307 (11): E1009–19. https://doi.org/10.1152/ajpendo.00364.2014.

Chen K., Wang T., Li Y., et al. Rhodojaponin VI indirectly targets Cav2.2 channels via N-ethylmaleimide-sensitive fusion protein to alleviate neuropathic pain. Acta Pharm Sin B. 2023; 13 (3): 1326–36. https://doi.org/10.1016/j.apsb.2023.01.021.

Huang S.K., Lu C.W., Lin T.Y., Wang S.J. Neuroprotective role of the B vitamins in the modulation of the central glutamatergic neurotransmission. CNS Neurol Disord Drug Targets. 2022; 21 (4): 292–301. https://doi.org/10.2174/1871527320666210902165739.

The authors declare that there are no conflicts of interest present.